Department of Nephrology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, China.
Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Keele, United Kingdom.
JAMA Netw Open. 2022 Feb 1;5(2):e2147171. doi: 10.1001/jamanetworkopen.2021.47171.
People with type 2 diabetes have greater risk for some site-specific cancers, and risks of cancers differ among racial and ethnic groups in the general population of Aotearoa New Zealand. The extent of ethnic disparities in cancer risks among people with type 2 diabetes in New Zealand is unclear.
To compare the risks of 21 common adult cancers among Māori, Pasifika, and New Zealand European individuals with type 2 diabetes in New Zealand from 1994 to 2018.
DESIGN, SETTING, AND PARTICIPANTS: This population-based, matched cohort study used data from the primary care audit program in Auckland, New Zealand, linked with national cancer, death, and hospitalization registration databases, collected from January 1, 1994, to July 31, 2018, with follow-up data obtained through December 31, 2019. Using a tapered matching method to balance potential confounders (sociodemographic characteristics, lifestyle, anthropometric and clinical measurements, treatments [antidiabetes, antihypertensive, lipid-lowering, and anticoagulant], period effects, and recorded duration of diabetes), comparative cohorts were formed between New Zealand European and Māori and New Zealand European and Pasifika individuals aged 18 years or older with type 2 diabetes. Sex-specific matched cohorts were formed for sex-specific cancers.
Māori, Pasifika, and New Zealand European (reference group) ethnicity.
The incidence rates of 21 common cancers recorded in nationally linked databases between 1994 and 2018 were the main outcomes. Weighted Cox proportional hazards regression was used to assess ethnic differences in risk of each cancer.
A total of 33 524 adults were included: 15 469 New Zealand European (mean [SD] age, 61.6 [13.2] years; 8522 [55.1%] male), 6656 Māori (mean [SD] age, 51.2 [12.4] years; 3345 [50.3%] female), and 11 399 Pasifika (mean [SD] age, 52.8 [12.7] years; 5994 [52.6%] female) individuals. In the matched New Zealand European and Māori cohort (New Zealand European: 8361 individuals; mean [SD] age, 58.9 [12.9] years; 4595 [55.0%] male; Māori: 5039 individuals; mean [SD] age, 51.4 [12.3] years; 2542 [50.5%] male), significant differences between New Zealand European and Māori individuals were identified in the risk for 7 cancers. Compared with New Zealand European individuals, the hazard ratios (HRs) among Māori individuals were 15.36 (95% CI, 4.50-52.34) for thyroid cancer, 7.94 (95% CI, 1.57-40.24) for gallbladder cancer, 4.81 (95% CI, 1.08-21.42) for cervical cancer (females only), 1.97 (95% CI, 1.30-2.99) for lung cancer, 1.81 (95% CI, 1.08-3.03) for liver cancer, 0.56 (95% CI, 0.35-0.90) for colon cancer, and 0.11 (95% CI, 0.04-0.27) for malignant melanoma. In the matched New Zealand European and Pasifika cohort (New Zealand European: 9340 individuals; mean [SD] age, 60.6 [13.1] years; 4885 [52.3%] male; Pasifika: 8828 individuals; mean [SD] age, 53.1 [12.6] years; 4612 [52.2%] female), significant differences between New Zealand European and Pasifika individuals were identified for 6 cancers. Compared with New Zealand European individuals, HRs among Pasifika individuals were 25.10 (95% CI, 3.14-200.63) for gallbladder cancer, 4.47 (95% CI, 1.25-16.03) for thyroid cancer, 0.48 (95% CI, 0.30-0.78) for colon cancer, 0.21 (95% CI, 0.09-0.48) for rectal cancer, 0.21 (95% CI, 0.07-0.65) for malignant melanoma, and 0.01 (95% CI, 0.01-0.10) for bladder cancer.
In this cohort study, differences in the risk of 21 common cancers were found between New Zealand European, Māori, and Pasifika groups of adults with type 2 diabetes in New Zealand from 1994 to 2018. Research into the mechanisms underlying these differences as well as additional screening strategies (eg, for thyroid and gallbladder cancers) appear to be warranted.
患有 2 型糖尿病的人群患某些特定部位癌症的风险更高,并且在新西兰奥特亚罗瓦的一般人群中,不同种族和族裔群体的癌症风险也存在差异。在新西兰,2 型糖尿病患者的癌症风险在不同族裔群体之间存在多大程度的差异尚不清楚。
比较新西兰从 1994 年至 2018 年期间,21 种常见成人癌症在毛利人、太平洋岛民和新西兰欧洲人群中的 2 型糖尿病患者中的发病风险。
设计、地点和参与者:这项基于人群的匹配队列研究使用了新西兰奥克兰初级保健审计计划的数据,这些数据与国家癌症、死亡和住院登记数据库相关联,收集时间从 1994 年 1 月 1 日至 2018 年 7 月 31 日,通过 2019 年 12 月 31 日获得随访数据。通过使用锥形匹配方法平衡潜在的混杂因素(社会人口统计学特征、生活方式、人体测量和临床测量、治疗方法[抗糖尿病、抗高血压、降脂和抗凝]、时期效应和记录的糖尿病持续时间),在年龄在 18 岁或以上的新西兰欧洲人和毛利人以及新西兰欧洲人和太平洋岛民之间形成了 2 型糖尿病的比较队列。针对不同性别,形成了性别特异性匹配队列以研究不同性别癌症。
毛利人、太平洋岛民和新西兰欧洲(参照组)族裔。
1994 年至 2018 年期间在全国性数据库中记录的 21 种常见癌症的发病率是主要结局。使用加权 Cox 比例风险回归评估了每种癌症的风险在不同族裔之间的差异。
共纳入 33524 名成年人:15469 名新西兰欧洲人(平均[标准差]年龄为 61.6[13.2]岁;8522 名[55.1%]男性)、6656 名毛利人(平均[标准差]年龄为 51.2[12.4]岁;3345 名[50.3%]女性)和 11399 名太平洋岛民(平均[标准差]年龄为 52.8[12.7]岁;5994 名[52.6%]女性)。在匹配的新西兰欧洲人和毛利人队列(新西兰欧洲人:8361 名;平均[标准差]年龄为 58.9[12.9]岁;4595 名[55.0%]男性;毛利人:5039 名;平均[标准差]年龄为 51.4[12.3]岁;2542 名[50.5%]男性)中,新西兰欧洲人和毛利人之间在 7 种癌症的发病风险方面存在显著差异。与新西兰欧洲人相比,毛利人罹患甲状腺癌的风险比为 15.36(95%CI,4.50-52.34)、胆囊癌为 7.94(95%CI,1.57-40.24)、女性宫颈癌为 4.81(95%CI,1.08-21.42)、肺癌为 1.97(95%CI,1.30-2.99)、肝癌为 1.81(95%CI,1.08-3.03)、结肠癌为 0.56(95%CI,0.35-0.90)、恶性黑色素瘤为 0.11(95%CI,0.04-0.27)。在匹配的新西兰欧洲人和太平洋岛民队列(新西兰欧洲人:9340 名;平均[标准差]年龄为 60.6[13.1]岁;4885 名[52.3%]男性;太平洋岛民:8828 名;平均[标准差]年龄为 53.1[12.6]岁;4612 名[52.2%]女性)中,新西兰欧洲人和太平洋岛民之间在 6 种癌症的发病风险方面存在显著差异。与新西兰欧洲人相比,太平洋岛民罹患胆囊癌的风险比为 25.10(95%CI,3.14-200.63)、甲状腺癌为 4.47(95%CI,1.25-16.03)、结肠癌为 0.48(95%CI,0.30-0.78)、直肠癌为 0.21(95%CI,0.09-0.48)、恶性黑色素瘤为 0.21(95%CI,0.07-0.65)、膀胱癌为 0.01(95%CI,0.01-0.10)。
在这项队列研究中,新西兰从 1994 年至 2018 年期间,2 型糖尿病的新西兰欧洲、毛利人和太平洋岛民成人中,21 种常见癌症的发病风险存在差异。有必要对这些差异的潜在机制以及额外的筛查策略(例如甲状腺癌和胆囊癌)进行研究。